Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) EBIT (2023 - 2025)

Historic EBIT for Incannex Healthcare (IXHL) over the last 3 years, with Q3 2025 value amounting to -$6.8 million.

  • Incannex Healthcare's EBIT fell 863.45% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 2250.92%. This contributed to the annual value of -$23.8 million for FY2025, which is 2081.16% up from last year.
  • Per Incannex Healthcare's latest filing, its EBIT stood at -$6.8 million for Q3 2025, which was down 863.45% from -$7.5 million recorded in Q2 2025.
  • Incannex Healthcare's 5-year EBIT high stood at -$4.9 million for Q3 2023, and its period low was -$9.7 million during Q2 2024.
  • Moreover, its 3-year median value for EBIT was -$6.8 million (2025), whereas its average is -$6.7 million.
  • The largest annual percentage gain for Incannex Healthcare's EBIT in the last 5 years was 3731.68% (2024), contrasted with its biggest fall of 2784.14% (2024).
  • Incannex Healthcare's EBIT (Quarter) stood at -$8.0 million in 2023, then skyrocketed by 37.32% to -$5.0 million in 2024, then plummeted by 35.77% to -$6.8 million in 2025.
  • Its EBIT was -$6.8 million in Q3 2025, compared to -$7.5 million in Q2 2025 and -$5.0 million in Q1 2025.